Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Baxdrostat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : AstraZeneca
Deal Size : $1,800.0 million
Deal Type : Acquisition
Acquisition of CinCor Pharma Complete
Details : The acquisition bolsters AstraZeneca’s cardiorenal pipeline by adding CIN-107 (baxdrostat), an aldosterone synthase inhibitor (ASI) for blood pressure lowering in treatment-resistant hypertension, to its cardiorenal portfolio.
Brand Name : CIN-107
Molecule Type : Small molecule
Upfront Cash : $1,300.0 million
February 24, 2023
Lead Product(s) : Baxdrostat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : AstraZeneca
Deal Size : $1,800.0 million
Deal Type : Acquisition
Lead Product(s) : Baxdrostat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CIN-107 (baxdrostat) is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland, in development for patient with treatment-resistant hypertension and primary ...
Brand Name : CIN-107
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 21, 2023
Lead Product(s) : Baxdrostat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Baxdrostat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : AstraZeneca
Deal Size : $1,800.0 million
Deal Type : Acquisition
AstraZeneca to Acquire Cin Cor Pharma to Strengthen Cardiorenal Pipeline
Details : The acquisition will bolster AstraZeneca’s cardiorenal pipeline by adding CinCor’s candidate drug, CIN-107 (baxdrostat), an aldosterone synthase inhibitor (ASI) for blood pressure lowering in treatment-resistant hypertension.
Brand Name : CIN-107
Molecule Type : Small molecule
Upfront Cash : $1,300.0 million
January 09, 2023
Lead Product(s) : Baxdrostat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : AstraZeneca
Deal Size : $1,800.0 million
Deal Type : Acquisition
Lead Product(s) : Baxdrostat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Baxdrostat (CIN-107) is highly selective, oral small molecule inhibitor of aldosterone synthase, enzyme responsible for synthesis of aldosterone in adrenal gland, for the treatment-resistant hypertension and primary aldosteronism.
Brand Name : CIN-107
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 28, 2022
Lead Product(s) : Baxdrostat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Baxdrostat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Baxdrostat is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland, in development for patient populations with significant unmet medical needs.
Brand Name : CIN-107
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 07, 2022
Lead Product(s) : Baxdrostat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Baxdrostat
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Baxdrostat (CIN-107) is a highly selective, once-daily, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland, in development for treatment-resistant hypertension and primary a...
Brand Name : CIN-107
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 25, 2022
Lead Product(s) : Baxdrostat
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Baxdrostat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Baxdrostat (CIN-107) is highly selective, oral small molecule inhibitor of aldosterone synthase, in development for patient populations with significant unmet medical needs, including treatment-resistant hypertension and primary aldosteronism.
Brand Name : CIN-107
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 21, 2022
Lead Product(s) : Baxdrostat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Baxdrostat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Baxdrostat (CIN-107) is highly selective, oral small molecule inhibitor of aldosterone synthase, enzyme responsible for synthesis of aldosterone in adrenal gland, in development for patient populations with significant unmet medical needs.
Brand Name : CIN-107
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 12, 2022
Lead Product(s) : Baxdrostat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Baxdrostat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Baxdrostat (CIN-107) is highly selective, oral small molecule inhibitor of aldosterone synthase, enzyme responsible for synthesis of aldosterone in adrenal gland, in development for patient populations with significant unmet medical needs.
Brand Name : CIN-107
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 28, 2022
Lead Product(s) : Baxdrostat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Baxdrostat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Baxdrostat (CIN-107) is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland, in development for patient populations with significant unmet medical needs.
Brand Name : CIN-107
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 22, 2022
Lead Product(s) : Baxdrostat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?